心理健康领域中组合基因与个体基因药物基因组学检测：关于背景及临床效用影响的观点
Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility.
作者信息
Winner Joel G, Dechairo Bryan
机构信息
Assurex Health Inc., Mason, Ohio.
出版信息
Yale J Biol Med. 2015 Nov 24;88(4):375-82. eCollection 2015 Dec.
Abstract
Pharmacogenomic testing in mental health has not yet reached its full potential. An important reason for this involves differentiating individual gene testing (IGT) from a combinatorial pharmacogenomic (CPGx) approach. With IGT, any given gene reveals specific information that may, in turn, pertain to a smaller number of medications. CPGx approaches attempt to encompass more complete genomic information by combining moderate risk alleles and synergistically viewing the results from the perspective of the medication. This manuscript will discuss IGT and CPGx approaches to psychiatric pharmacogenomics and review the clinical validity, clinical utility, and economic parameters of both.
摘要
心理健康领域的药物基因组学检测尚未充分发挥其潜力。造成这种情况的一个重要原因涉及区分个体基因检测（IGT）和组合药物基因组学（CPGx）方法。采用IGT时，任何特定基因都会揭示特定信息，这些信息反过来可能只涉及较少数量的药物。CPGx方法试图通过组合中度风险等位基因并从药物角度协同查看结果来涵盖更完整的基因组信息。本文将讨论精神科药物基因组学的IGT和CPGx方法，并综述两者的临床有效性、临床实用性和经济参数。
相似文献
1
Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility.
Yale J Biol Med. 2015 Nov 24;88(4):375-82. eCollection 2015 Dec.
2
Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation.
Curr Med Res Opin. 2015;31(9):1633-43. doi: 10.1185/03007995.2015.1063483. Epub 2015 Jul 23.
3
Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders.
Per Med. 2018 Nov;15(6):481-494. doi: 10.2217/pme-2018-0074. Epub 2018 Sep 26.
4
Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients.
Am J Manag Care. 2015 Jun 1;21(6):e357-65.
5
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Pharmacogenomics J. 2015 Oct;15(5):443-51. doi: 10.1038/tpj.2014.85. Epub 2015 Feb 17.
6
Pharmacogenomics in Psychiatric Practice.
Clin Lab Med. 2016 Sep;36(3):507-23. doi: 10.1016/j.cll.2016.05.001.
7
Real-world experience of using combinatorial pharmacogenomic test in children and adolescents with depression and anxiety.
J Psychiatr Res. 2022 Feb;146:83-86. doi: 10.1016/j.jpsychires.2021.12.037. Epub 2021 Dec 21.
8
Clinical Implications of Combinatorial Pharmacogenomic Tests Based on Cytochrome P450 Variant Selection.
Front Genet. 2021 Sep 28;12:719671. doi: 10.3389/fgene.2021.719671. eCollection 2021.
9
Analytical validation of a psychiatric pharmacogenomic test.
Per Med. 2018 May 1;15(3):189-197. doi: 10.2217/pme-2017-0094. Epub 2018 Feb 7.
10
Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients.
J Geriatr Psychiatry Neurol. 2020 Nov;33(6):324-332. doi: 10.1177/0891988719892341. Epub 2019 Dec 17.
引用本文的文献
1
An Effective Method to Facilitate Personalized and Precise Medicine for Schizophrenia Treatment Based on Pharmacogenomics.
Psychiatry Clin Psychopharmacol. 2021 Jun 1;31(2):148-156. doi: 10.5152/pcp.2021.20176. eCollection 2021 Jun.
2
Mental Health Prescribers' Perceptions on the Use of Pharmacogenetic Testing in the Management of Depression in the Middle East and North Africa Region.
Pharmgenomics Pers Med. 2023 May 30;16:503-518. doi: 10.2147/PGPM.S410240. eCollection 2023.
3
Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021.
Front Pharmacol. 2022 Apr 14;13:907131. doi: 10.3389/fphar.2022.907131. eCollection 2022.
4
Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial).
Trials. 2021 Dec 11;22(1):896. doi: 10.1186/s13063-021-05775-8.
5
Clinical Implications of Combinatorial Pharmacogenomic Tests Based on Cytochrome P450 Variant Selection.
Front Genet. 2021 Sep 28;12:719671. doi: 10.3389/fgene.2021.719671. eCollection 2021.
6
Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ont Health Technol Assess Ser. 2021 Aug 12;21(13):1-214. eCollection 2021.
7
Pharmacogenetics and Depression: A Critical Perspective.
Psychiatry Investig. 2019 Sep;16(9):645-653. doi: 10.30773/pi.2019.06.16. Epub 2019 Aug 29.
8
Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.
Front Pharmacol. 2019 Feb 19;10:99. doi: 10.3389/fphar.2019.00099. eCollection 2019.
9
Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders.
Pharmgenomics Pers Med. 2018 Nov 19;11:211-222. doi: 10.2147/PGPM.S146110. eCollection 2018.
10
Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools.
BMC Psychiatry. 2017 Feb 8;17(1):60. doi: 10.1186/s12888-017-1230-5.
本文引用的文献
1
The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.
Br J Clin Pharmacol. 2015 Dec;80(6):1438-46. doi: 10.1111/bcp.12743. Epub 2015 Oct 28.
2
Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation.
Curr Med Res Opin. 2015;31(9):1633-43. doi: 10.1185/03007995.2015.1063483. Epub 2015 Jul 23.
3
CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Clin Toxicol (Phila). 2015 Jul;53(6):501-10. doi: 10.3109/15563650.2015.1049355. Epub 2015 May 22.
4
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29.
5
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Pharmacogenomics J. 2015 Oct;15(5):443-51. doi: 10.1038/tpj.2014.85. Epub 2015 Feb 17.
6
Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings.
Am J Manag Care. 2014 May;20(5):e146-56.
7
8
Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
Int Rev Psychiatry. 2013 Oct;25(5):554-71. doi: 10.3109/09540261.2013.838944.
9
Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.
Pharmacogenet Genomics. 2013 Oct;23(10):535-48. doi: 10.1097/FPC.0b013e3283649b9a.
10
Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine.
Pharmacogenet Genomics. 2013 Sep;23(9):494-7. doi: 10.1097/FPC.0b013e328363688d.
Zotero 插件